NCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
Clinical Trials
11 trialsNCT04943952 2021-08-03
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Jazz Pharmaceuticals
Approved for marketing
NCT03070093 2021-04-20
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Astellas Pharma Inc
Approved for marketing
NCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT03245424 2018-07-24
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
Agios Pharmaceuticals, Inc.
Approved for marketing
NCT01869803 2018-03-02
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Wake Forest University Health Sciences
Approved for marketing
NCT01592136 2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT02437019 2017-03-20
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Janssen-Cilag Farmaceutica Ltda.
Approved for marketing
NCT02136511 2014-10-28
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Gilead Sciences
Approved for marketing
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT00905593 2012-07-18
ENACT
Novartis
Approved for marketing